The effect of probiotics in treatment of patients undergoing breast cancer chemotherapy

The effect of probiotics on quality of life and inflammatory and oxidative stress biomarkers in patients undergoing breast cancer chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191006045001N1

Enrollment

Registered

2020-01-26

Start date

2019-10-30

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Probiotic capsule containing 4 strains of Bifidobacterium lactis (1/8×109 units per gram), Lactobacillus acidophilus (1/8×109 units per gram), Bifidobacterium bifid

Eligibility

Sex/Gender

Female

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Breast cancer without metastases Patients candidate for chemotherapy for the first time after surgery or before surgery. Breast cancer just diagnosed

Exclusion criteria

Exclusion criteria: Consuming probiotic supplements within 8 weeks prior to the study Taking other forms of probiotics including probiotic yogurt and other fermented foods Taking antioxidants supplements Patients with metabolic syndrome Patients with chronic infections

Design outcomes

Primary

Measure	Time frame
Quality of life of patients. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: patient health Questionnaire 9.	—

Secondary

Measure	Time frame
Gastrointestinal disorders. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical examination by oncology specialist.;Anemia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test ( hemoglobin<10g/dl).;Leukopenia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test (white blood cell<4000).;Thrombocytopenia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test (Platelet<100000).;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Gastrointestinal disorders. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical examination by oncology specialist.;Anemia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test ( hemoglobin<10g/dl).;Leukopenia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test (white blood cell<4000).;Thrombocytopenia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: CBC test (Platelet<100000).;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoud Fakharian Kashani

Day hospital, Tehran

info@daygeneralhospital.ir+98 21 8879 7111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026